X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (17811) 17811
Publication (1861) 1861
Newsletter (997) 997
Newspaper Article (719) 719
Book Review (237) 237
Book Chapter (112) 112
Magazine Article (60) 60
Transcript (44) 44
Conference Proceeding (23) 23
Trade Publication Article (20) 20
Dissertation (17) 17
Book / eBook (12) 12
Web Resource (8) 8
Data Set (5) 5
Streaming Video (5) 5
Report (3) 3
Presentation (2) 2
Government Document (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (13860) 13860
index medicus (12202) 12202
bevacizumab (9007) 9007
angiogenesis (7395) 7395
female (7246) 7246
angiogenesis inhibitors - therapeutic use (6464) 6464
male (6279) 6279
oncology (5943) 5943
cancer (5537) 5537
vascular endothelial growth factor (5072) 5072
middle aged (4595) 4595
ophthalmology (4555) 4555
aged (4461) 4461
angiogenesis inhibitors (4383) 4383
endothelial growth-factor (4244) 4244
vascular endothelial growth factor a - antagonists & inhibitors (4227) 4227
animals (3879) 3879
angiogenesis inhibitors - administration & dosage (3526) 3526
care and treatment (3355) 3355
treatment outcome (3176) 3176
chemotherapy (3129) 3129
antibodies, monoclonal, humanized (2946) 2946
adult (2833) 2833
research (2728) 2728
metastasis (2657) 2657
intravitreal injections (2625) 2625
tumors (2334) 2334
macular degeneration (2276) 2276
ranibizumab (2240) 2240
aged, 80 and over (2152) 2152
vegf (2080) 2080
angiogenesis inhibitors - adverse effects (1958) 1958
therapy (1935) 1935
mice (1921) 1921
retrospective studies (1919) 1919
antibodies, monoclonal - therapeutic use (1860) 1860
neovascularization (1755) 1755
medicine & public health (1729) 1729
antibodies, monoclonal, humanized - therapeutic use (1723) 1723
analysis (1708) 1708
tomography, optical coherence (1682) 1682
angiogenesis inhibitors - pharmacology (1647) 1647
expression (1634) 1634
drug therapy (1553) 1553
cancer therapies (1508) 1508
health aspects (1507) 1507
neovascularization, pathologic - drug therapy (1504) 1504
antineoplastic combined chemotherapy protocols - therapeutic use (1483) 1483
antineoplastic agents - therapeutic use (1455) 1455
clinical trials (1427) 1427
fluorescein angiography (1403) 1403
follow-up studies (1352) 1352
pharmacology & pharmacy (1349) 1349
antibodies, monoclonal - administration & dosage (1347) 1347
vascular endothelial growth factor a - metabolism (1323) 1323
colorectal cancer (1246) 1246
antibodies, monoclonal, humanized - administration & dosage (1228) 1228
visual acuity - physiology (1198) 1198
cell line, tumor (1186) 1186
visual acuity (1162) 1162
prognosis (1113) 1113
tumor angiogenesis (1110) 1110
neoplasms - drug therapy (1082) 1082
studies (1082) 1082
surgery (1072) 1072
eye diseases (1064) 1064
prospective studies (1052) 1052
article (1049) 1049
breast cancer (1045) 1045
choroidal neovascularization - drug therapy (1042) 1042
physiological aspects (1034) 1034
patients (1024) 1024
survival (1012) 1012
medical research (1008) 1008
antineoplastic agents (1006) 1006
development and progression (971) 971
antimitotic agents (963) 963
kinases (941) 941
diabetic retinopathy (939) 939
proteins (932) 932
bevacizumab - therapeutic use (922) 922
avastin (912) 912
hematology, oncology and palliative medicine (909) 909
macular degeneration - drug therapy (885) 885
phase-ii trial (875) 875
trial (875) 875
apoptosis (871) 871
disease-free survival (857) 857
macular edema - drug therapy (851) 851
injections (848) 848
medicine (829) 829
abridged index medicus (823) 823
cell biology (817) 817
hypoxia (817) 817
risk factors (805) 805
colorectal neoplasms - drug therapy (802) 802
monoclonal antibodies (801) 801
research article (795) 795
endothelial growth factors (784) 784
antibodies, monoclonal - adverse effects (776) 776
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (19129) 19129
French (208) 208
German (178) 178
Japanese (135) 135
Spanish (35) 35
Chinese (34) 34
Portuguese (24) 24
Polish (23) 23
Russian (22) 22
Czech (17) 17
Hungarian (16) 16
Romanian (12) 12
Korean (7) 7
Dutch (4) 4
Italian (4) 4
Finnish (3) 3
Turkish (3) 3
Hebrew (2) 2
Norwegian (2) 2
Swedish (2) 2
Icelandic (1) 1
Persian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Oncologist, ISSN 1083-7159, 01/2012, Volume 17, Issue 1, pp. 15 - 25
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2014, Volume 370, Issue 8, pp. 709 - 722
In patients with glioblastoma, the addition of bevacizumab to radiotherapy and temozolomide induction therapy and the use of bevacizumab maintenance therapy... 
CONCOMITANT RADIOCHEMOTHERAPY | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | RECURRENT GLIOBLASTOMA | CLINICAL-TRIALS | MALIGNANT GLIOMAS | QUALITY-OF-LIFE | RESPONSE ASSESSMENT CRITERIA | MULTIFORME | HIGH-GRADE GLIOMA | ENDOTHELIAL GROWTH-FACTOR | Dacarbazine - adverse effects | Dacarbazine - therapeutic use | Humans | Middle Aged | Induction Chemotherapy | Male | Glioblastoma - radiotherapy | Bevacizumab | Young Adult | Dacarbazine - analogs & derivatives | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Brain Neoplasms - mortality | Brain Neoplasms - radiotherapy | Angiogenesis Inhibitors - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Kaplan-Meier Estimate | Combined Modality Therapy | Brain Neoplasms - drug therapy | Disease-Free Survival | Quality of Life | Aged | Glioblastoma - drug therapy | Glioblastoma - mortality | Dosage and administration | Research | Temozolomide | Drug therapy, Combination | Drug therapy | Glioblastoma multiforme | Nuclear magnetic resonance--NMR | Intravenous administration | Glucocorticoids | Brain cancer | Body weight | Glioblastoma | Radiation therapy | Survival | Patients | Quality of life | Vascular endothelial growth factor | Index Medicus | Abridged Index Medicus | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2013, Volume 24, Issue 9, pp. 2335 - 2341
Journal Article
Ophthalmology, ISSN 0161-6420, 2007, Volume 114, Issue 5, pp. 855 - 859
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2011, Volume 365, Issue 26, pp. 2484 - 2496
The addition of bevacizumab to chemotherapy (15 mg/kg for six cycles) followed by extended therapy with bevacizumab every 3 weeks for a total of 15 months of... 
CARBOPLATIN-PACLITAXEL | 1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | INTERGROUP TRIAL | GYNECOLOGIC-ONCOLOGY-GROUP | SOLID TUMORS | ANGIOGENESIS | CYCLOPHOSPHAMIDE | EXPRESSION | INTRAPERITONEAL CISPLATIN | III TRIAL | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carboplatin - administration & dosage | Combined Modality Therapy | Ovarian Neoplasms - mortality | Neoplasms, Glandular and Epithelial - surgery | Bevacizumab | Disease-Free Survival | Neoplasms, Glandular and Epithelial - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Glandular and Epithelial - drug therapy | Survival Analysis | Angiogenesis Inhibitors - therapeutic use | Carcinoma, Ovarian Epithelial | Quality of Life | Female | Paclitaxel - administration & dosage | Angiogenesis Inhibitors - adverse effects | Ovarian Neoplasms - drug therapy | Ovarian Neoplasms - surgery | Drugs | Dose-response relationship (Biochemistry) | Product/Service Evaluations | Drug therapy | Ovarian cancer | Risk groups | Body weight | Clinical trials | Survival | Angiogenesis | Chemotherapy | Womens health | Paclitaxel | Carboplatin | Vascular endothelial growth factor | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
JAMA, ISSN 0098-7484, 06/2017, Volume 317, Issue 23, pp. 2392 - 2401
IMPORTANCE: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic... 
MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | FIRE-3 | THERAPY | FOLFIRI PLUS CETUXIMAB | PHASE-II | IRINOTECAN | OXALIPLATIN | FLUOROURACIL | TUMORS | PROGRESSION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - therapeutic use | United States | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Cetuximab - adverse effects | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - secondary | Aged | Genes, ras | Organoplatinum Compounds - adverse effects | Chemotherapy | Usage | Care and treatment | Research | Colorectal cancer | Cancer | Drugs | Medical research | Colorectal carcinoma | Clinical trials | Cytotoxicity | Patients | Survival | K-Ras protein | Bevacizumab | Metastases | Survival analysis | Irinotecan | Randomization | Oxaliplatin | Monoclonal antibodies | Tumors
Journal Article